Enzon Commences Phase II Trial of PEG-SN38
Enzon Pharmaceuticals, Inc. announced that it has opened its first Phase II trial for PEG-SN38, its novel proprietary cancer compound. The trial is open at multiple centers throughout the United States for patients diagnosed with metastatic colon cancer. [more...]
